CRISPR used to treat Duchenne muscular dystrophy in mice
A study has shown that CRISPR can be used as a regenerative technique to treat Duchenne muscular dystrophy, which could be developed as a therapeutic option for humans.
List view / Grid view
A study has shown that CRISPR can be used as a regenerative technique to treat Duchenne muscular dystrophy, which could be developed as a therapeutic option for humans.
CRISPR is the buzzword of the moment in the drug discovery industry – mainly due to its potential to correct disease-causing mutations. However, those using the technology need to be mindful that it is used responsibly, and possible risks are considered before use. Mark Behlke discusses the potential of CRISPR…
A team has used a lentiviral capsid-based bionanoparticle system to deliver CRISPR-Cas9 gene editing therapies, reducing undesired effects.
Scientists have discovered a molecular pathway that contributes to PAH development, which may lead to a new drug target for the disease.
The number of oligonucleotide-based platforms on the market is constantly increasing and has led to the emergence of innovative nucleic acid-based therapeutic modalities such as CRISPR-Cas, sgRNAs or mRNAs.
In this In-Depth Focus are articles on how genomics could revolutionise clinical treatment and an insight into the promise and pitfalls of using CRISPR.
A study has used CRISPR-Cas9 to treat obesity and type 2 diabetes symptoms in mice, highlighting the potential use in humans.
Researchers have created a new technique for activating genes using bacteria which could have therapeutic uses.
A tumour-targeted CRISPR gene editing system encapsulated in a nanogel could halt the growth of triple-negative breast cancer.
Modern cell biology requires a wide variety of applications to keep up with the numerous exciting directions that research takes us. Detection technologies ranging from fluorescence to cellular imaging have become common in today’s laboratories.
Researchers may have fundamentally altered the way scientists study brain diseases with new CRISPR technology.
A research team have used genome editing to correct two of the mutations that cause cystic fibrosis.
Scientists report how editing a portion of stem cells with CRISPR-Cas9 is sufficient for long-term reactivation of therapeutic haemoglobin.
Salk scientists discover a pair of enzymes that drive non-small-cell lung cancer by promoting inflammation which could inform the development of new therapies.
Researchers have successfully used a no-cut CRISPR gene editing technique as a therapy for muscular dystrophy in mice models.